Related Experiment Video
Updated: Jun 29, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function
Shashwati Basak1, Deepa Pookot, Emily J Noonan
1Department of Urology, San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA.
Abstract:
Androgen receptor (AR) is a ligand-activated transcription factor belonging to the steroid hormone receptor family and is very important for the development and progression of prostate cancer. The soy isoflavone genistein has been shown previously to down-regulate AR in androgen-dependent prostate cancer cell lines such as LNCaP. However, the mechanism(s) by which AR is down-regulated by genistein is still not known fully. We show a new mechanism by which genistein inhibits AR protein levels. We show that genistein-treated LNCaP cells exhibit increased ubiquitination of AR, suggesting that AR protein is down-regulated via a proteasome-mediated pathway. AR is normally stabilized by the chaperone activity of the heat shock protein Hsp90. The increased ubiquitination of AR after genistein treatment is attributed to decreased Hsp90 chaperone activity as assessed by its increased functionally inactive acetylated form. Consistent with this result, we find that HDAC6, which is a Hsp90 deacetylase, is inhibited by the antiestrogenic activity of genistein. Hence, in this study, we elucidate a novel mechanism of AR down-regulation by genistein through inhibition of HDAC6-Hsp90 cochaperone function required to stabilize AR protein. Our results suggest that genistein could be used as a potential chemopreventive agent for prostate cancers along with known inhibitors of HDAC6 and Hsp90.
Insights
Genistein, a soy isoflavone, reduces prostate cancer
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- Androgen receptor (AR) is crucial for prostate cancer development.
- Genistein (soy isoflavone) previously showed AR down-regulation in prostate cancer cells.
- The exact mechanism of genistein-induced AR down-regulation remained unclear.
Purpose of the Study:
- To elucidate the novel mechanism by which genistein down-regulates AR protein levels.
- To investigate the role of Hsp90 chaperone activity and HDAC6 in genistein's effect.
Main Methods:
- Assessed AR ubiquitination in genistein-treated LNCaP cells.
- Evaluated Hsp90 chaperone activity and acetylation status.
- Investigated the effect of genistein on HDAC6 activity.
Main Results:
- Genistein treatment increased AR ubiquitination, indicating proteasomal degradation.
- Genistein decreased Hsp90 chaperone activity by promoting its acetylation.
- Genistein inhibited HDAC6, a Hsp90 deacetylase, reducing its cochaperone function.
Conclusions:
- Genistein down-regulates AR by inhibiting the HDAC6-Hsp90 complex, disrupting AR stabilization.
- Genistein represents a potential chemopreventive agent for prostate cancer.
- Combination therapy with genistein and HDAC6/Hsp90 inhibitors may be beneficial.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Abnormal Proliferation
Negative Regulator Molecules
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

